Skip to main content

Table 3 Immune outcome in DPX-0907-treated patients

From: First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients

Total patients recruited   23
Full treatment received   22
Evaluable   18
Immune response (IR)  
Positive IR in: Breast cancer 3/3 (100%)
  Ovarian cancer 5/6 (83%)
  Breast/Ovarian 8/9 (89%)
  Prostate cancer 3/9 (33%)
  All patients 11/18 (61%)
  Dose A 5/9 (56%)
  Dose B 6/9 (67%)
Positive IR after: 1 vaccination 8/11 (73%)
  2 vaccinations 2/11 (18%)
  3 vaccinations 1/11 (9%)
Positive IR at: 1 time point 2/11 (18%)
  2 time points 7/11 (64%)
  3 time points 2/11 (18%)
Existing IR at: SD73 7/11 (64%)